Just out: the short interest for the latest reporting period (settlement date Sept 15) was basically flat, down just 31k shares or less than half of one percent. But with the avg daily share volume reduced (from 210 K down to 159K) the Days to Cover jumped from 33 to 43....so the brew keeps getting primed for a possible (upward) explosion.
" Do any of you have sources or means to get a sense on how they are doing?"
1. This year a family member had a routine colonoscopy. at an outpatient surgi-center in Brooklyn NY.
When I asked him about Novadaq, he seemed mystified...but when asked about SPY, he quickly said,
oh yes, SPY Scope. He was familiar with it and was using it in his practice.
2. A year or two ago a friend's daughter underwent a double mastectomy at a major hospital in New York City (I believe it was Columbia Presbyterian). The surgeons there loved SPY iand wanted the hospital to buy more units.
Hope this helps.
Right now Novadaq has its hands full--- closing sales with hospital administrators, tending to its clinical studies and educating surgeons about Pinpoint/Luna.. The noise will take care of itself. I believe that the torch will be lit when Investors Business Daily features the SPY technology.
Yes, Arun nailed it!
The company is finally firing on all cylinders.
Especially liked that our guys are ready to announce new upgrades/products, just waiting on the Stryker announcment. Already in the top German hospitals...that was news to me.
The latest reporting period (as of July 31) shows an additional 1 % increase, or 68K shares, bringing the grand total to 6,709,590 shares or roughly 13% of the float (expressed another way, this represents about 12% of the outstanding shares.. Either way, this pile is beginning to look like serious money.
" Arun is leaning towards the International being as big or bigger than the US market".
This is news to me...is this just a hunch, or if not, what exactly are you referencing?
I thank you for your reply.
Couldn't agree more with you...thanks for your post.
Maybe you'd like to apply for a job as Novadaq's public relations director.
11) multi year service contracts with hospitals will bolster recurring revenue.
12). Arun was in Japan "last week" to train sales staff...all international agreements still " intact."
13) One time expenses "moving out" while revenues will be increasing.
14) Wasn't aware of the FDA recall on some Allargan non human artificial l tissues.. Arun contrasted that
with Novadaq's cleaner, less septic product from Dermacell.
15) Wasn''t aware of the ongoing LUNA study
16) Total reset of the numbers. starting with 1Q, 2015, making YOY comparisons meaningless
(too many moving parts for meaningful comparisons) So a brand new company has been reborn,
The only non Arun presentation that I can remember was given by Roger Deck, CFO.
and former manager of operations for Novadaq. He's the one who stated that there was a "dramatic change " in Novadaq's business. He seemed like a pretty sincere person when we spoke last November at the Investor day conference in NYC. So I'm keeping my fingers crossed. As per your question, I believe what you heard was indeed true.
Short interest just hit a brand new high, albeit ever so slightly at 6.641 M as of July 15.
Time for a straddle?
Something is going to pop at earnings. imo.
Let's just hope it goes in our direction!
Yes, something is going on, but what?
There's been no earnings warning from management.
They could easily be sued if their past statements of 40% growth fell apart without warning investors first.
Somebody is buying, as the share price has been trending up for a full month (since the breakout on June 10). According to Investors Business Daily charts, the relative strength of nvdq's share price has risen since the bottom of June 10. I'm somewhat comforted by Roger's comment on a recent webcast, that there's been a "dramatic" change for the better in the business. So let's hurry up and wait for the earnings CC.